Search

everythinglearnresearchcommunity

for

Search:↓

High and low doses of prednisolone helped 62% of children with severe alopecia regrow hair with some weight gain and mild acne as side effects.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

A patient with complete hair loss regrew all her hair using tofacitinib.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Finasteride helps female-pattern hair loss.

New understanding and treatments for hair loss are improving, but more research is needed.

New alopecia treatments aim for better results and fewer side effects.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

A medication for skin rash also unexpectedly treated hair loss in a patient.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

New treatments for hair loss show promise but need more research to confirm safety and effectiveness.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

JAK inhibitors may soon be a safe and effective treatment for alopecia areata.

Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.